Compare CADL & TPVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CADL | TPVG |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.4M | 182.2M |
| IPO Year | 2021 | 2013 |
| Metric | CADL | TPVG |
|---|---|---|
| Price | $4.97 | $4.87 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 5 |
| Target Price | ★ $19.71 | $6.00 |
| AVG Volume (30 Days) | ★ 1.2M | 602.2K |
| Earning Date | 03-12-2026 | 03-04-2026 |
| Dividend Yield | N/A | ★ 18.44% |
| EPS Growth | ★ 58.62 | N/A |
| EPS | N/A | ★ 1.05 |
| Revenue | ★ $125,000.00 | N/A |
| Revenue This Year | N/A | $7.67 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.25 | $4.48 |
| 52 Week High | $7.24 | $7.53 |
| Indicator | CADL | TPVG |
|---|---|---|
| Relative Strength Index (RSI) | 48.90 | 42.59 |
| Support Level | $4.58 | N/A |
| Resistance Level | $5.42 | $5.70 |
| Average True Range (ATR) | 0.26 | 0.22 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 68.13 | 43.41 |
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the firm's operations are located across the United States.